The AUTACE That Degrades KRAS and Engages CD8 + T Cells for the Treatment of KRAS/TP53 Co‐Mutant Tumors
Advanced Science · 2026-07 · 13 (37)
DOI: 10.1002/advs.202518455 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 07.04.2026. Verfasst von Luo Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, Women and Children's Hospital of Chongqing Medical University, Chongqing, China. Hauptthemen laut MEDLINE: CD8-Positive T-Lymphocytes, Proto-Oncogene Proteins p21(ras), Tumor Suppressor Protein p53. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chongqing Technological Innovation and Application Development, Natural Science Foundation of Chongqing, China Postdoctoral Science Foundation.
Abstract (Originalsprache)
KRAS and TP53 co‐mutations are frequently associated with highly aggressive, therapy‐resistant cancers with limited treatment options. In this study, we have developed Autophagy‐Targeting Chimera–T‐cell Engager (AUTACE), a bifunctional nanoplatform composed of T‐cell receptor–engineered T (TCR‐T) cell–derived nanovesicles that display anti‐CD3 antibodies and encapsulate perfluoropentane (PFP) together with KPY, an autophagy‐targeting degrader active against mutant KRAS, for the treatment of KRAS/TP53 co‐mutant tumors. AUTACE targets tumors via TP53‐specific TCRs, elicits antitumor CD8 + T‐cell responses through surface anti‐CD3 antibodies, and employs low‐intensity focused ultrasound (LIFU) to trigger controlled release of KPY to degrade mutant KRAS. This achieved targeted tumor elimination. The therapeutic efficacy of AUTACE was validated in mice bearing PANC‐1 and MIA PaCa‐2 tumors. A comprehensive assessment of the post‐treatment tumor microenvironment revealed that KRAS degradation increased tumor‐derived CCL5 levels, thereby promoting CD8 + T‐cell recruitment and amplifying antitumor responses. Thus, AUTACE represents a promising strategy for the treatment of KRAS/TP53 co‐mutant tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Laboratory Medicine, Women and Children's Hospital of Chongqing Medical University, Chongqing, China.
- Department of Laboratory Medicine, Chongqing Health Center for Women and Children, Chongqing, China.
- Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing, China.
- Department of Ultrasound, the First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
ORCID-Profile: Luo Li
Förderung
- Chongqing Technological Innovation and Application Development
- Natural Science Foundation of Chongqing
- China Postdoctoral Science Foundation
- Chongqing Science and Health Joint Medical Research Project
- Chongqing Municipal Education Commission
- Natural Science Foundation of Chongqing Municipality
Zitieren
APA
Li, L., Li, B., Hao, Y., Pang, B., Li, P., Li, C., & Tang, Y. (2026). The AUTACE That Degrades KRAS and Engages CD8 + T Cells for the Treatment of KRAS/TP53 Co‐Mutant Tumors. Advanced Science, 13(37). https://doi.org/10.1002/advs.202518455
Vancouver
Li L, Li B, Hao Y, Pang B, Li P, Li C, et al. The AUTACE That Degrades KRAS and Engages CD8 + T Cells for the Treatment of KRAS/TP53 Co‐Mutant Tumors. Advanced Science. 2026;13(37). doi:10.1002/advs.202518455
BibTeX
@article{Li2026,
author = {Li, Luo and Li, Bolin and Hao, Yanan and Pang, Bo and Li, Pan and Li, Chunli and Tang, Yu},
title = {The AUTACE That Degrades KRAS and Engages CD8 + T Cells for the Treatment of KRAS/TP53 Co‐Mutant Tumors},
journal = {Advanced Science},
year = {2026},
volume = {13},
number = {37},
doi = {10.1002/advs.202518455}
}
EUVIMED